HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma.

Abstract
Dysregulation of protein expression is associated with most diseases including cancer. MS-based proteomic analysis is widely employed as a tool to study protein dysregulation in cancers. Proteins that are differentially expressed in head and neck squamous cell carcinoma (HNSCC) cell lines compared to the normal oral cell line could serve as biomarkers for patient stratification. To understand the proteomic complexity in HNSCC, we carried out iTRAQ-based MS analysis on a panel of HNSCC cell lines in addition to a normal oral keratinocyte cell line. LC-MS/MS analysis of total proteome of the HNSCC cell lines led to the identification of 3263 proteins, of which 185 proteins were overexpressed and 190 proteins were downregulated more than twofold in at least two of the three HNSCC cell lines studied. Among the overexpressed proteins, 23 proteins were related to DNA replication and repair. These included high-mobility group box 2 (HMGB2) protein, which was overexpressed in all three HNSCC lines studied. Overexpression of HMGB2 has been reported in various cancers, yet its role in HNSCC remains unclear. Immunohistochemical labeling of HMGB2 in a panel of HNSCC tumors using tissue microarrays revealed overexpression in 77% (54 of 70) of tumors. The HMGB proteins are known to bind to DNA structure resulting from cisplatin-DNA adducts and affect the chemosensitivity of cells. We observed that siRNA-mediated silencing of HMGB2 increased the sensitivity of the HNSCC cell lines to cisplatin and 5-FU. We hypothesize that targeting HMGB2 could enhance the efficacy of existing chemotherapeutic regimens for treatment of HNSCC. All MS data have been deposited in the ProteomeXchange with identifier PXD000737 (http://proteomecentral.proteomexchange.org/dataset/PXD000737).
AuthorsNazia Syed, Sandip Chavan, Nandini A Sahasrabuddhe, Santosh Renuse, Gajanan Sathe, Vishalakshi Nanjappa, Aneesha Radhakrishnan, Remya Raja, Sneha M Pinto, Anand Srinivasan, T S Keshava Prasad, Kotteazeth Srikumar, Harsha Gowda, Vani Santosh, David Sidransky, Joseph A Califano, Akhilesh Pandey, Aditi Chatterjee
JournalProteomics (Proteomics) Vol. 15 Issue 2-3 Pg. 383-93 (Jan 2015) ISSN: 1615-9861 [Electronic] Germany
PMID25327479 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Chemical References
  • Antineoplastic Agents
  • HMGB2 Protein
  • RNA, Small Interfering
  • Cisplatin
  • Fluorouracil
Topics
  • Antineoplastic Agents (pharmacology)
  • Carcinoma, Squamous Cell (drug therapy, genetics, pathology)
  • Cell Line
  • Cell Line, Tumor
  • Cisplatin (pharmacology)
  • Drug Resistance, Neoplasm
  • Fluorouracil (pharmacology)
  • HMGB2 Protein (analysis, genetics)
  • Head and Neck Neoplasms (drug therapy, genetics, pathology)
  • Humans
  • Proteomics
  • RNA Interference
  • RNA, Small Interfering (genetics)
  • Squamous Cell Carcinoma of Head and Neck
  • Tandem Mass Spectrometry

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: